The loudness-dependence of the auditory evoked potential (LDAEP) slope may be inversely related to serotonin (5-HT) neurotransmission. Thus, steep LDAEPs tend to predict a positive response to selective serotonin reuptake inhibitor (SSRI) antidepressants, which augment 5-HT. However, LDAEPs also predict outcome to antidepressants indirectly altering 5-HT (e.g. bupropion). Hence, the LDAEP's predicative specificity and sensitivity to antidepressant response/outcome remains elusive. Scalp N1, P2 and N1/P2 LDAEP slopes and standardized low resolution brain electromagnetic tomography (sLORETA)-localized N1 and P2 LDAEP slopes were assessed in depressed individuals (N = 51) at baseline, 1 and 12 weeks post-treatment with one of three antidepressant regimens [escitalopram (ESC) + bupropion (BUP), ESC or BUP]. Clinical response was greatest with ESC + BUP at week 1. Treatment responders had steep N1 sLORETA-LDAEP baseline slopes while non-responders had shallow ones. P2 sLORETA-LDAEP slope increases at 1 week existed in responders; decreases were noted in non-responders. Exploratory analyses indicated that more BUP and ESC responders versus non-responders had steep baseline N1 sLORETA-LDAEP slopes. Additionally, slight decreases in scalp P2 LDAEP by week 1 existed for ESC treatment, while slope increases existed with ESC + BUP treatment. Only baseline N1 sLORETA-LDAEP discriminated treatment responders/non-responders. This work confirms that certain LDAEP measures are associated with treatment outcome and appear to be differentially modulated with varying antidepressant drug regimens, though this should be confirmed using larger samples.
Introduction
Though many pharmacotherapies exist for treating major depressive disorder (MDD), the majority of patients do not remit with initial treatment (Thase, 2003) . Additionally, those who do benefit from antidepressants typically experience weeks-long delays before symptom relief. Although selective serotonin reuptake inhibitors (SSRIs) continue to be the most commonly used antidepressants (Marcus and Olfson, 2010) , their therapeutic response variability is high. Some evidence suggests that SSRI efficacy may be enhanced by coadministering other drugs, such as bupropion (Lam et al., 2004; Spier, 1998) , and that remission rates can be increased and clinical improvement expedited if drug combinations are given at treatment initiation (Blier et al., 2010) . Currently, no established markers exist for predicting response to specific antidepressant pharmacotherapies; such markers would aid in optimizing treatments. One such candidate may be electroencephalogram (EEG)-derived measures to an auditory challenge.
High 5-hydroxytryptamine (5-HT; serotonin) neurotransmission exists in primary sensory cortices, such as the auditory cortex, and is likely implicated in modulating sensory processing (Hegerl et al., 2001) . Two EEG-derived auditory evoked potentials (AEPs), the N1 and P2, are generated in auditory cortices; their peak-to-peak amplitude (N1/P2) correlates positively with intensity. By plotting N1/P2 amplitude against intensity, a loudness dependence of the AEP (LDAEP; or intensity-dependent AEP, IDAEP) slope is constructed, which appears to be inversely related to 5-HT activity. As cortical hyper-activation with increasing intensity could be damaging, 5-HT activity may inhibit excess neural firing (Juckel et al., 1999) . Thus, low dorsal raphe nucleus 5-HT pre-activation is thought to be
